Global Markets

Everest starts operations at China mRNA vaccine plant

Shanghai Everest Medicines has started operations in its $130 million mRNA vaccine production facility, located in Jiashan, Zhejiang Province. In September 2021, Everest announced a $500 million two-part mRNA deal with Providence Therapeutics of Calvary, Canada. Initially, Everest acquired China-Asia rights to Providence’s mRNA Phase II COVID-19 vaccine and then began a 50/50 global collaboration for two additional Providence mRNA prophylactic or therapeutic products. Everest said it has completed industrial scale technology transfer of the mRNA platform along with other tasks that will allow…

2023 predictions: Sustainability, synthetic biology & prepping for the next pandemic

With business returning to more-or-less normal after nearly three COVID-fixated years, a panel of experts looks to the potential trends and topics 2023 might bring. Our ability to discuss and debate industry trends via online panels may be one of the silver linings from nearly three years of living and working in a COVID-influenced world, and thus the latest BioProcess Insider State of the Industry discussion took place on such a medium. While our panel of experts spoke fluidly on…

Innovative payment models needed for CGT market access, says experts

Current payment models must change to make gene therapies more accessible, say experts. The cost of gene therapies continues to be a hot topic in the industry. Last month, CSL Behring’s one-time gene therapy Hemgenix (etranacogene dezaparvovec) for hemophilia B received approval from the US Food and Drug Administration (FDA) with a list price of $3.5 million, making it the most expensive single-dose drug on the market. With such hefty costs, various firms are looking at solutions that could potentially drive…

Digitization: Biopharma must keep up with rest of the world, says Cytiva

“You can watch your pizza’s progress on an app, but our customers cannot watch their batches of cells being cultured or have simple access batch data,” says Cytiva CEO Emmanuel Ligner. Welcome to the second section of BioProcess Insider’s two-part interview with Emmanuel Ligner, who has served as CEO of Cytiva since 2017. If you have not yet read the first part where Ligner discusses how messenger RNA (mRNA) will play a major role in healthcare in 2023 and beyond,…

China plant becomes latest in Thermo Fisher biomanufacturing network

The 860,000 square-foot facility in Hangzhou is Thermo Fisher’s first single-use manufacturing site in the Asia-Pacific region. The facility opened its doors last week offering customers clinical and commercial drug substance and drug product capabilities, housing Thermo Fisher’s HyPerforma single-use bioreactors and associated single-use equipment to a 2,000 L scale. The size of the capital expenditure has not been disclosed, and when asked the firm did not divulge how long it has taken for the facility to be built. The…

BioProcess Insider State of the Industry — December 2022 Panel Discussion

This panel discussion features: Christopher Peterson, Associate Director, Latham Biopharm Group; Jason Slingsby, Chief Business & Corporate Development Officer, Oxford Biomedica; Dr. Ger Brophy, Executive Vice President of Biopharma Production, Avantor. BioProcess Insider’s State of the Industry takes a deeper look into the recent business news affecting the biomanufacturing industry, picking apart the numbers and highlighting potential trends. With a panel of industry experts, editor Dan Stanton will discuss recent M&A in the bioprocess space, bottlenecks within the manufacturing sector,…

The CDMO space does not have the capacity to meet fill-finish demand, says Lonza

Pipeline expansions are placing pressure on fill-finish capabilities and have caused a surge of investment in infrastructure, says Peter Droc, head of drug product services at Lonza. Swiss contract development manufacturing organization (CDMO) Lonza has made a string of investments to bolster its fill-finish capabilities. In July 2022, the firm forked out $521 million to construct a commercial large-scale fill-finish facility at its site in Stein, Switzerland. And less than a year before this – at the same plant –…

COVID cull: Valneva cutting workforce and manufacturing ops

The discontinuation of its COVID program has led Valneva to resize its operations and question the use of its Livingston, UK facility. French vaccine firm Valneva SE developed VLA2001, an inactivated COVID-19 vaccine candidate, approved in the European Union (EU) in January 2022. Despite initial orders to supply up to 100 million doses in the UK, and a further 60 million doses in Europe last year, the changing COVID-19 pandemic landscape meant Valneva’s vaccine never achieved the rollout seen with…

Neurophth enters $140m gene therapy collaboration with Cyagen

Wuhan Neurophth has announced a $140 million agreement to use Cyagen’s AI platform to discover novel AAV vectors. Cyagen is a Santa Clara, California gene therapy contract research organization (CRO) with offices in China and Japan that offers genetically modified rodent models. Neurophth is developing gene therapies for ophthalmology indications. The company’s lead drug recently started a Phase III trial for ND4-mediated Leber’s hereditary optic neuropathy (ND4-LHON) with plans to conduct trials of the drug in China and the US.…

ten23 looks to on-body-injectors to reduce healthcare costs

CDMO ten23 health is supporting customers to develop an on-body-injector platform, which it says could lower overall treatment costs. Ten23, a contract development manufacturing organization (CDMO) focused on developing and commercializing injectable biopharmaceuticals met BioProcess Insider at CPHI, Frankfurt to discuss its on-body-injector activity. “Instead of holding and keeping in position a syringe for the time of injection, on-body-injectors are stuck to the body,” explained Michael Petersen, ten23’s chief commercial officer. “A button is pressed, and a small motor is…